Shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) increased 1.82% and closed at $0.0896 after opening 0.09 with the overall traded volume of 882,087.00 shares. The company’s Market capitalization reached to $12.57 million, $137.80 million outstanding shares. Its low price was $0.08 and highest price was $0.09. The Distance from 50 day Simple moving average was -27.65% and Distance from 200 day Simple moving average -60.66%.The EPS is -0.21.
ImmunoCellular Therapeutics Ltd (IMUC) announced financial results for the second quarter of 2016.
For the quarter ended June 30, 2016, ImmunoCellular incurred a net loss of $5.3 million, or $0.06 per basic and diluted share, compared to a net loss of $3.2 million, or $0.03 per basic and diluted share, for the quarter ended June 30, 2015.
During the second quarter 2016, ImmunoCellular incurred $4.4 million of research and development expenses compared to $2.3 million in the prior year quarter while general and administrative expenses remained relatively constant between periods. The $2.1 million increase in research and development expenses primarily reflects the additional expenses associated with the phase 3 trial of ICT-107.
For the six months ended June 30, 2016, ImmunoCellular incurred a net loss of $11.0 million, or $0.12 per basic and diluted share, compared to a net loss of $4.6 million, or $0.05 per basic and diluted share, During the six months ended June 30, 2016, ImmunoCellular incurred $9.2 million in research and development expenses compared to $4.4 million in the prior year.
Shares of CIGNA Corporation (NYSE:CI) decreased -0.21% and closed at $120.90 after opening 121.56 with the overall traded volume of 570,185.00 shares. The company’s Market capitalization reached to $30.95 billion, $256.57 million outstanding shares. Its low price was $120.68 and highest price was $122.25. The Distance from 50 day Simple moving average was -6.40% and Distance from 200 day Simple moving average was -9.12%. The EPS is 7.70.
CIGNA Corporation (CI) announced new, expanded access and choice to affordable telehealth services for millions of Americans enrolled in Cigna administered medical and behavioral health plans for 2017.
In 2017, Cigna will significantly expand its telehealth coverage by adding AMWELL (by American Well) to its existing offering of MDLIVE – both as a standard telehealth benefit for most* of Cigna’s U.S. employer-sponsored group health plans, as well as many of its individual health plans on and off public marketplace exchanges. Both services operate national networks of board-certified doctors that are able to treat minor medical conditions such as allergies, cold and flu and sinusitis.
In January, Cigna will also add telehealth video consultations for its health plan customers by using the company’s contracted behavioral health professionals. Customers who have mental health/substance abuse benefits with Cigna will have the option for individual therapy or medication management through video-based services. There is no additional cost for these behavioral services to customers or their employers, with the same cost share applying to video-based services as face-to-face office visits.